Bruker Corporation · NASDAQ:BRKR
Bruker — Jefferies 2022 London Healthcare Conference
12 slides from Bruker's conference presentation, Nov 15, 2022
Slide 1: BRKR Jefferies Conference Presentation
BRUKER CORPORATION (NASDAQ: BRKR) BRKR Jefferies Conference Presentation November 15, 2022 Gerald Herman, Executive Vice President & CFO Justin Ward, Senior Director, Investor Relations & Corporate Development
Slide 2: Safe Harbor Statement
BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
Slide 3: YTD Q3 2022 Financials and FY22 Guidance
YTD Q3 2022 FINANCIALS AND FY22 GUIDANCE YTD Q3 2022 Robust Revenue Growth with Solid Margin Expansion Raised FY2022 Guidance Forecasts Strong Finish to Year YTD Q3 2022 Financials (YoY) FY 2022 Guidance (as of Nov. 3) ❖ Revenue increased $87.9M, or +5.1% ❖ Revenue Growth of +1.5% to +3.5% (vs. prio
Slide 4: Innovation and Multiyear Transformation Delivering Shareholder Value
TRANSFORMATION UPDATE Innovation and Multiyear Transformation Delivering Shareholder Value Accelerated Revenue Growth & Margin Expansion, With Top-Tier ROIC Revenue Growth Acceleration Significant non-GAAP Operating Non-GAAP EPS DD CAGR Margin expansion, ROIC >20% $2.4B $2.5B 28% ROIC $2.31 $2.10 $2
Slide 5: Our Strategy Focuses on Accelerating Revenue Growth While Delivering Margin Expansion
DUAL STRATEGY Our Strategy Focuses on Accelerating Revenue Growth While Continuing to Deliver Sustainable Margin Expansion Project Accelerate 2.0(1) Operational Excellence + Innovation & growth + Commercial excellence + Significant margin expansion + Product R&D excellence + Expanded large TAMs + Ex
Slide 6: Expanding Portfolio of Instruments & Software for Unbiased Proteomics, Multiomics, Structural Biology
P ROTEOMICS , M ULTIOM ICS , STRUCTUR AL & F UNCTIONAL BIOLOGY Expanding Portfolio of Instruments & Software for: Unbiased Proteomics, Multiomics, Structural/Functional Biology, and More Bruker Addressable TAM: $6B+ © 2022 Bruker + -Bruker Innovation with Integrity | June 9, 2022 | 6
Slide 7: Tims/PASEF CCS Enabling 4D Multiomics Revolution
P ROTEOMICS , M ULTIOM ICS , STRUCTUR AL & F UNCTIONAL BIOLOGY Tims/PASEF CCS Enabling 4D Multiomics Revolution © 2022 Bruker + -Bruker Innovation with Integrity | June 9, 2022 | 7
Slide 8: Expanding Portfolio of Instruments & Software for Spatial Biology & Single-Cell Omics
SP ATIAL BIOLOG Y & SP ATIAL M ULTIOMICS Expanding Portfolio of Instruments & Software for Spatial Biology & Single- Cell Omics: Canopy, MALDI HiPLEX-IHC, and soon Acuity Spatial Genomics true single-cell & subcellular resolution ❖ MALDI HiPLEX-IHC utilizes Bruker partner/investment AmberGen’s ❖ Cel
Slide 9: Inscopix, Inc, recently acquired by Bruker
M&A Inscopix, Inc, recently acquired by Bruker Market leader in a rapidly-growing neuroscience research niche ▪ Inscopix, Inc a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. Founded in 2011. In use in over 600 researc
Slide 10: Appendix
Appendix 10
Slide 11: Faster Growth from Six Expanded High-Growth, High-Margin Initiatives
PROJECT ACCELERATE 2.0 Faster Growth from Six Expanded High-Growth, High-Margin Initiatives Unbiased 4D-Proteomics & Unbiased Epiproteomics, Functional Consumables, Scientific Proteomics & Structural Biology, SCP Software & Aftermarket Multiomics Proteomics, PTMs, multiomic Consumables, assays, serv
Slide 12: ;
;